TNFα-mediated *Hsd11b1* binding of NF-κB p65 is associated with suppression of 11β-HSD1 in muscle

Craig L Doig, Jamila Bashir, Agnieszka E Zielinska, Mark S Cooper, Paul M Stewart and Gareth G Lavery

School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham B15 2TT, UK

Abstract

The activity of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone (11-dehydrocorticosterone (11-DHC)) (in mice) into the active glucocorticoid (GC) cortisol (corticosterone in mice), can amplify tissue GC exposure. Elevated TNFα is a common feature in a range of inflammatory disorders and is detrimental to muscle function in diseases such as rheumatoid arthritis and chronic obstructive pulmonary disease. We have previously demonstrated that 11β-HSD1 activity is increased in the mesenchymal stromal cells (MSCs) by TNFα treatment and suggested that this is an autoregulatory anti-inflammatory mechanism. This upregulation was mediated by the P2 promoter of the *Hsd11b1* gene and was dependent on the NF-κB signalling pathway. In this study, we show that in contrast to MSCs, in differentiated C2C12 and primary murine myotubes, TNFα suppresses *Hsd11b1* mRNA expression and activity through the utilization of the alternative P1 promoter. As with MSCs, in response to TNFα treatment, NF-κB p65 was translocated to the nucleus. However, ChIP analysis demonstrated that the direct binding was seen at position −218 to −245 bp of the *Hsd11b1* gene’s P1 promoter but not at the P2 promoter. These studies demonstrate the existence of differential regulation of 11β-HSD1 expression in muscle cells through TNFα/p65 signalling and the P1 promoter, further enhancing our understanding of the role of 11β-HSD1 in the context of inflammatory disease.

Key Words

- glucocorticoid
- inflammation
- metabolism
- muscle

Introduction

The endogenous glucocorticoid (GC) concentrations are determined by the activity of the hypothalamo-pituitary–adrenal axis, with tissue and intracellular exposure further augmented through the activity of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone (11-dehydrocorticosterone (11-DHC) in mice) to the active GC cortisol (corticosterone in mice) (Stewart 2003, 2005, Zhang *et al.* 2013). The ability of 11β-HSD1 to elevate cellular GC levels has led it to be implicated in the modulation of a number of metabolic and inflammatory disease processes (Hardy *et al.* 2008, Morgan *et al.* 2009, Kaur *et al.* 2010). Therefore, the identification of factors and mechanisms regulating 11β-HSD1 expression and activity could further highlight its physiological and pathophysiological roles.

Elevation of the pro-inflammatory cytokine TNFα is a cardinal feature of a range of inflammatory disorders...
(Bamias et al. 2013, Golikova et al. 2013, Khosravi et al. 2013, Moelants et al. 2013). We have previously reported that TNF-α increases 11β-HSD1 expression and activity in the cells of the mesenchymal lineage, including osteoblasts and fibroblasts. In these cells, it was demonstrated that this was mediated through the classical Hsd11b1 P2 promoter and that the induction of 11β-HSD1 activity by TNF-α was dependent upon NF-κB signalling. However, no direct binding site of the NF-κB p65 subunit to the P2 promoter could be identified. Basal NF-κB signalling plays a fundamental role in skeletal muscle myogenesis; however, during prolonged inflammatory stress, TNF-α-mediated NF-κB activity can abrogate myogenesis, inhibiting differentiation and increasing catabolic processes contributing to muscle wasting (Yamaki et al. 2012). Previous research has demonstrated down-regulation of 11β-HSD1 activity when mature C2C12 muscle cell myotubes are stimulated with TNF-α and it was proposed that NF-κB binding to sites in the Hsd11b1 promoter may be directly responsible for this regulation (Aubry & Odermatt 2009).

In this study, we demonstrate that in contrast to TNF-α upregulation of 11β-HSD1 in mesenchymal stromal cells (MSCs) acting through indirect NF-κB regulation at the P2 promoter, in C2C12 and primary murine myotubes TNF-α stimulates the NF-κB p65 subunit to bind the alternate Hsd11b1 P1 promoter and mediate inhibition of 11β-HSD1 activity.

Materials and methods

C2C12 cell culture

Mouse skeletal muscle cell line C2C12 (European Collection of Cell Cultures, Salisbury, Wiltshire, UK) myoblasts were maintained in DMEM (PAA Laboratories, Yeovil, Somerset, UK), high-glucose, supplemented with FBS (10%) penicillin/streptomycin (ten units) and incubated at 37 °C in the presence of 5% CO2. The media were replaced for every 48 h and the cells were split three times weekly. To differentiate myoblasts into myotubes, they were cultured to 70% confluence before addition of DMEM, high-glucose, supplemented with 5% horse serum and penicillin/streptomycin (ten units), and the media were replaced every 48 h.

Primary mouse muscle cell culture

Primary muscle dissection and culture of myotubes derived from muscle satellite cells were conducted as reported by Rosenblatt et al. (1995). Briefly, extensor digitorum longus (EDL) was dissected from mice at 5 weeks of age. These were digested in type I collagenase for 2 h. Individual fibres of the muscle were then disrupted gently using a glass pipette. Individual muscle fibre was then placed into 24-well plates coated with Matrigel and left for 72 h. After 72 h the satellite cells had migrated from the fibre and the fibres were removed from the plate, satellite cell proliferation media were added. Satellite cells-derived myoblasts were then cultured to confluence and differentiated to myotubes stable in culture for ~14 days. Treatments were for 24 h unless otherwise indicated and occurred in serum-free media using murine TNF-α (10 ng/ml); the vehicle control used was 0.1% BSA and dexamethasone (1 μM).

RNA extraction, RT-PCR and quantitative real-time PCR

Total RNA was isolated and extracted from cell lyases using TRI-Reagent (Sigma–Aldrich). The quality and quantity of RNA recovered were assessed by running on 1.5% agarose gel and Nanodrop spectrophotometer. RT-PCR used 1 μg RNA per sample and was carried out using the reverse transcription kit (CODE) Applied Biosciences (kit code is 4368814). Specific mRNA levels were determined using an ABI 7900 sequence detection system (Applied Biosystems). Reactions were carried out in 12.5 μl volumes on 384 well plates (Applied Biosystems) in a reaction buffer containing 2× Taqman Universal PCR Master Mix (Applied Biosystems). Primers and probes for specific genes were purchased in ‘Assay on Demand’ format from Applied Biosystems (IGF1:Mm00439560_m1, MYOD:Mm00521984_m1, TP53: Mm00480750_m1, H6PD:Mm00557617). These were normalised against 18S rRNA (Applied Biosystems) as an internal control. Raw data were recovered as CT values and analysed as per the 2−ΔΔCT method.

RT-PCR of alternative transcripts from the Hsd11b1 gene was carried out as described in Staab et al. (2011).

Western immunoblotting

Protein lysates were collected in RIPA buffer (50 mmol/l Tris pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mmol/l NaCl, 1 mmol/l EDTA), 1 mmol/l phenylmethylsulfonyl fluoride and protease inhibitor cocktail (Roche), stored at −80 °C (30 min), defrosted on ice and centrifuged at 4 °C (10 min, 11 269 g). The supernatant was recovered and total protein concentration was assessed by Bio-Rad assay. Total proteins (25 μg) were resolved on a 12% SDS–PAGE gel and transferred onto a nitrocellulose membrane. Primary antibodies used were mouse anti-p65 via Open Access. This work is licensed under a Creative Commons Attribution 3.0 Unported License http://creativecommons.org/licenses/by/3.0/deed.en_GB
(Santa Cruz Sc-8008), mouse anti-β-actin (Sigma–Aldrich A-5441), mouse anti-α-tubulin (Santa Cruz Sc-5286) and rabbit anti-11β-HSD1 (Ricketts et al. 1998).

Secondary antibodies (Dako, Ely, Cambridgeshire, UK) anti-mouse and anti-rabbit conjugated with HRP were added at a dilution of 1/5000. Equal loading of protein content was verified using β-actin and the bands were visualised using ECL detection system (GE Healthcare, Little Chalfont, Buckinghamshire, UK).

Chromatin immunoprecipitation

Chromatin immunoprecipitation was conducted using the EZ-ChIP kit from Millipore (Watford, Hertfordshire, UK). The C2C12 myotubes were differentiated in T175 volumes flasks. The cells were cross-linked with formaldehyde (1%) for 10 min at room temperature. Glycine at a final concentration of 125 mM was added to quench and left at room temperature for 5 min. The flasks were washed twice in ice-cold PBS and sonicated using a Bioruptor (Diagenode, Seraing, Belgium) to produce chromatin smears with an average size of 500–1000 bp. Chromatin immunoprecipitations were carried out using the anti-p65 (Santa Cruz Sc-8008) alongside IgG control. DNA recovery was conducted and SYBR green PCR was carried out using the primer sequences described in Table 1.

11β-HSD1 activity assay

Briefly, the cells were incubated with 100 nmol/l 11-DHC and tritiated tracer (³HA) made in-house was added to each well at 0.22 μCi/reaction. Steroids were then extracted using dichloromethane, separated using a mobile phase consisting of ethanol and chloroform (8:92) by thin layer chromatography and scanned using a Bioscan 3000 image analyser (Lablogic, Sheffield, South Yorkshire, UK). The calculations of 11-DHC (A) to corticosterone (B) were conducted as follows B/(A+B)×100=% Conversion.

Table 1

| Putative response element 1 | LEFT | Putative response element 1 | RIGHT |
|----------------------------|------|----------------------------|-------|
| Putative response element 2 | LEFT |
| Putative response element 2 | RIGHT |
| Putative response element 3 | LEFT |
| Putative response element 3 | RIGHT |
| NF-κB lκBx promoter LEFT | TAGCCAACAGCCACGAC |
| NF-κB lκBx promoter RIGHT | TACGCAAATTCGCCCATAC |
| − 10 kb 11β-HSD flanking LEFT | GTGAGCTCCCTTGCACTT |
| − 10 kb 11β-HSD flanking RIGHT | TAGCCAGCGTTTCCACTCTT |
| − 10 kb 11β-HSD flanking LEFT | TCTGAGGCAAAGCCAAGACT |
| − 10 kb 11β-HSD flanking RIGHT | TTCTGGGATGAACTGGATTG |
| − 10 kb 11β-HSD flanking LEFT | GGTTGAGCTCCCTTGCACTT |
| − 10 kb 11β-HSD flanking RIGHT | TAGCCAATCCAGCCATAACC |
| − 10 kb 11β-HSD flanking LEFT | TCTGAGGCAAAGCCAAGACT |
| − 10 kb 11β-HSD flanking RIGHT | TTCTGGGATGAACTGGATTG |

Statistical analysis

Data shown are mean ± s.e.m. of at least three independent experiments with statistical significance defined as P<0.05 (*P<0.05; **P<0.01; ***P<0.001) using unpaired Student’s t-test and were conducted with Prism (GraphPad, La Jolla, CA, USA). Statistical analysis on real-time PCR data was carried out on mean ΔCt values.

Results

TNFα induces p65 nuclear translocation in C2C12 cells

Treatment of cells with TNFα (10 ng/ml) for 1 or 2 h produced no overall change in p65 cell content. However, isolation of the nuclear fraction showed enrichment of p65 in the nucleus upon TNFα stimulation, validating a functional NF-κB signalling pathway in 5-day-differentiated C2C12 myotubes (Fig. 1A). To assess archetypal responses to TNFα, mRNA levels were examined for the cell-cycle arrest gene Tp53 (Tp53) and pro-growth pro-differentiation genes Igf1 and Myod1 (Fig. 1B). TNFα treatment induced a significant increase in TP53 and significant decrease in Igf1 and Myod1 levels, validating the functionality of the model as has been described previously (Frost et al. 2003, Langen et al. 2004, Schwarzkopf et al. 2006).

TNFα suppresses 11β-HSD1 mRNA and protein expression

TNFα treatment of C2C12 myotubes decreases 11β-HSD1 mRNA in comparison with controls. Furthermore, analysis of H6pdh (H6pdh) mRNA which is the enzyme that provides NADPH to support 11β-HSD1 activity showed no change (Fig. 2A; Lavery et al. 2006). To establish if this response was detectable at a protein level, myotubes were challenged with TNFα for 24 h and were examined for levels of 11β-HSD1 protein. TNFα treatment produced a significant decrease in the expression of 11β-HSD1 protein within myotubes, compared with vehicle control (Fig. 2B).

TNFα suppresses 11β-HSD1 enzyme activity

It is well established that 11β-HSD1 activity increases during the process of C2C12 differentiation into myotubes.
In order to establish the relative functional impact of TNFα on 11β-HSD1 enzyme activity, C2C12 cells were differentiated for 4 days and activity assessed or vehicle/TNFα-treated for a further day (5 day total). The conversion of 11-DHC to corticosterone by 11β-HSD1 increased from day 4 to day 5 (Fig. 3A). However, TNFα treatment at day 4 of differentiation for an additional day significantly reduced 11β-HSD1 activity, suppressing it to the level of 4-day differentiated cells (Fig. 3A). We also tested cells with a greater degree of differentiation, examining C2C12 cells at day 11 and day 12 (Fig. 3B). The conversion rate increased significantly from day 11 to day 12 and TNFα treatment on day 12 suppressed 11β-HSD1 activity back towards that of day 11, confirming a robust effect equivalent to the effect seen at the earlier day 4 and 5 time points. To endorse these findings, we prepared 7-day differentiated myotubes from primary EDL muscle. Again, we saw a significant suppression of 11β-HSD1 activity following 1-day treatment with TNFα, consistent with the data from the fully differentiated C2C12 cells (Fig. 3C).

These data suggest that the suppression of 11β-HSD1 activity in response to TNFα is unlikely to be due solely to delays in differentiation, as C2C12 and primary muscle cells were fully differentiated and may indicate a direct effect of a TNFα-dependent factor acting at the Hsd11b1 gene promoter to regulate the suppression of 11β-HSD1 expression.

**TNFα suppresses 11β-HSD1 at the level of transcription**

To establish if the downregulation of 11β-HSD1 occurred through a transcriptional mechanism, C2C12 myotubes were treated with TNFα in the presence and absence of anisomycin to inhibit protein synthesis. Accordingly, the suppression of 11β-HSD1 mRNA transcription in response to TNFα is unchanged in the presence of anisomycin, suggesting that the effect is primarily at the level of transcription and not the consequence of secondary protein synthesis (Fig. 4). We used dexamethasone as a control, as it is well known to induce 11β-HSD1 mRNA (Fig. 4). However, in the presence of anisomycin, the Dex-induced 11β-HSD1 increase is attenuated, indicating a requirement of secondary protein synthesis to elicit the response.
with all three depicted in Fig. 5B. ChIP analysis of samples amplified with primers for the putative p65-binding regions following p65 pull down indicated no enrichment of p65 binding in putative regions 1 and 3 in comparison with control IgG. However, putative region 2 demonstrates that TNFα induces an increase in the p65-binding levels in comparison with control and suggests active recruitment of the p65 protein to the Hsd11b1 P1 promoter. As a positive control, TNFα-treated C2C12 cells were analysed by ChIP for enrichment of p65 to a well-validated IκBα-binding site, and confirmatory of NF-κB activation, further endorsing the finding of TNFα-mediated NF-κB-binding associated with suppression of 11β-HSD1 expression and activity (Fig. 5B). Additionally, a 10 kb upstream sequence of Hsd11b1 was used to validate the absence of p65 as a negative control region and no TNFα enrichment was observed for this sequence (Fig. 5B).

Discussion

Stimulation of 11β-HSD1 activity following TNFα exposure has been described for early progenitor cells of the mesenchymal lineage, particularly in cells of human origin (Zhang et al. 2013). Similarly, in differentiated cells such as osteoblasts and adipocytes, TNFα increases 11β-HSD1 activity to enhance local GC generation (Cooper et al. 2001, Tomlinson et al. 2010). Indeed, a range of cytokines and molecules, including IL1β and lipopolysaccharide (LPS), can stimulate 11β-HSD1 (Ishii-Yonemoto et al. 2010), suggesting that increasing levels in comparison with control and suggests active recruitment of the p65 protein to the Hsd11b1 P1 promoter. As a positive control, TNFα-treated C2C12 cells were analysed by ChIP for enrichment of p65 to a well-validated IκBα-binding site, and confirmatory of NF-κB activation, further endorsing the finding of TNFα-mediated NF-κB-binding associated with suppression of 11β-HSD1 expression and activity (Fig. 5B). Additionally, a 10 kb upstream sequence of Hsd11b1 was used to validate the absence of p65 as a negative control region and no TNFα enrichment was observed for this sequence (Fig. 5B).

These data demonstrate that TNFα initiates activation of a factor not requiring protein synthesis that can act directly at the 11β-HSD1 promoter, and we hypothesised that this would most likely be the TNFα target NF-κB.

The Hsd11b1 P1 promoter contains a p65-binding site

Transcription of the Hsd11b1 gene is regulated by two promoter regions: P1 and P2 (Bruley et al. 2006), and we confirmed that both promoters were active in our differentiated C2C12 cells, with promoter P2 usage preferential to promoter P1 (Fig. 5A). As we hypothesised that NF-κB binding may be associated with 11β-HSD1 suppression, we conducted ChIP analysis on C2C12 cells treated with TNFα, assessing p65 binding at putative response elements in the Hsd11b1 P1 and P2 promoters. In silico analysis revealed three candidate sequences with resemblance to a consensus NF-κB-binding site (GGGACTTTCC), two of which occur within close proximity to each other and are located in the P1 promoter, upstream of exon 1a transcription start site.

**Figure 3**

TNFα suppresses 11β-HSD1 activity in C2C12 and primary mouse myotubes. (A) C2C12 control cells were differentiated for 5 days, TNFα treatments were added 24 h before being assayed for 11β-HSD1 activity. (B) C2C12 control cells were differentiated for 12 days, TNFα treatments were added 24 h before being assayed for 11β-HSD1 activity. Protein lysates from C2C12 cells differentiated for 5 and 12 days (+/− TNFα for 24 h) were subject to western immunoblots demonstrating p65 expression levels. (C) Primary myotubes differentiated from mouse EDL muscle satellite cells were treated with TNFα or control for 24 h before conducting being assayed for 11β-HSD1 activity (*P<0.05, **P<0.01, ***P<0.001).

**Figure 4**

TNFα reduces 11β-HSD1 mRNA independent of the presence of anisomycin. Myotubes were treated with TNFα or dexamethasone in the presence and absence of the protein synthesis inhibitor anisomycin. 11β-HSD1 mRNA was measured by RT-PCR using ribosomal 18S as a standard (*P<0.05).
11β-HSD1 is a mechanism to initiate the process of inflammatory resolution through increased local GC generation. GCs are well documented to stimulate 11β-HSD1 expression and activity in most cell types including myocytes (Morgan et al. 2009). However, following muscle cell TNFα exposure, 11β-HSD1 activity is suppressed, with the effect mediated through p65 signalling and independent of secondary protein synthesis.

The best-established transcriptional regulators of Hsd11b1 gene expression for a range of human and murine cell types are the members of CCAATT/enhancer-binding protein (C/EBP) family. Hsd11b1 P1 promoter regulation of C/EBPα and C/EBPβ has been described previously (Balazs et al. 2008) and C/EBPα is regarded as a positive regulator of 11β-HSD1 transcription in hepatocytes with C/EBPβ acting as a repressor (Ignatova et al. 2009). However, in adipocyte and adipose tissue, C/EBPβ is an activator required to mediate the GC induction and cytokine regulation of 11β-HSD1 (Sai et al. 2008). More recently it has been established that an elevated ratio of C/EBPβ-liver enriched inhibitor protein and liver-enriched activator protein isoforms can downregulate 11β-HSD1 expression (Esteves et al. 2012). These data collectively represent an evidence for both the positive and negative regulation of 11β-HSD1 through transcriptional mechanisms in mature cells.

Here, we demonstrate that in both a murine skeletal muscle cell line and primary cultured myotubes 11β-HSD1 expression and activity are suppressed following TNFα exposure, with anisomycin experiments attributing this effect at the level of transcriptional regulation. This led us to search for potential TNFα-stimulated-NF-κB-binding motifs in the Hsd11b1 P1 and P2 promoters, using the cis-regulatory element database (Robertson et al. 2006). Taking the three strongest targets from the in silico
analysis, we used ChIP to identify a p65-binding sequence in the sequence motif located in the P2 promoter region (Fig. 5B) and associated this with the down-regulation of 11β-HSD1.

In contrast to our findings in muscle, adipocytes from p65 overexpression transgenic mice had elevated 11β-HSD1 at the mRNA and protein level, but show no evidence for direct gene regulation (Lee et al. 2013). In this context, NF-κB was acting as a positive regulator in a model of chronic systemwide p65 activation, indicating that 11β-HSD1 regulation is complex, with a number of tissue- and context-specific factors requiring consideration.

With this in mind, these data presented here represent the effects mediated following a single acute dose of TNFz, so biological interpretation in the context of that seen in another tissue type subjected to chronic TNFz stimulation should be cautious. TNFz-mediated regulation of 11β-HSD1 is part of a cellular response within muscle that targets a diverse set of transcriptionally regulated genes (Li et al. 2013). It may be that the suppressive effect observed is coordinated with the general suppression of myogenic differentiation, and dependent on interacting transcription factor and co-regulator availability. We have previously shown that in myoblasts response to TNFz by 11β-HSD1 is positively regulated, but in mature myotubes 11β-HSD1 is negatively regulated. This shift in regulation could in part be controlled at the level of Hsd11b1 P1 and P2 promoters utilisation during commitment and progression through myogenic differentiation that ultimately determines overall 11β-HSD1 expression and activity.

We demonstrate that 11β-HSD1 suppression is observed in differentiated C2C12 and primary myotubes and emphasise the important role of coordinated Hsd11b1 P1 and P2 promoters usage to control TNFz-regulated 11β-HSD1 activity. Further experiments are now required to expand this novel TNFz/NF-κB-mediated transcriptional suppression of 11β-HSD1 activity in the context of inflammatory disorders that can severely impact upon muscle structure and function.

Reference statement

Aubry EM & Odermatt A 2009 Retinoic acid reduces glucocorticoid sensitivity in C2C12 myotubes by decreasing 11β-hydroxysteroid dehydrogenase type I and glucocorticoid receptor activities. Endocrinology 150 2700-2708. (doi:10.1210/en.2008-1618)

Balazs Z, Schweizer RA, Frey FJ, Rohner-Jeanrenaud F & Odermatt A 2008 DHEA induces 11-HSD2 by acting on CCAAT/enhancer-binding proteins. Journal of the American Society of Nephrology 19 92–101. (doi:10.1681/ASN.2007030263)

Bamias G, Dahman MI, Arsenneau KO, Guanzon M, Gruska D, Pizarro TT & Cominelli F 2013 Intestinal-specific TNFs overexpression induces Crohn’s-like ileitis in mice. PLoS ONE 8 e72594. (doi:10.1371/journal.pone.0072594)

Bruley C, Lyons V, Worsley AG, Wild MD, Darlington GD, Morton NM, Seckl JR & Chapman KE 2006 A novel promoter for the 11β-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPα independent. Endocrinology 147 2879–2885. (doi:10.1210/en.2005-1621)

Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M & Stewart PM 2001 Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Journal of Bone and Mineral Research 16 1037–1044. (doi:10.1359/jbmr.2001.16.6.1037)

Esteses CI, Kelly V, Begay V, Man TY, Morton NM, Leutz A, Seckl JR & Chapman KE 2012 Regulation of adipocyte 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) by CCAAT/enhancer-binding protein (C/EBP) β isoforms, LIP and LAP. PLoS ONE 7 e37953. (doi:10.1371/journal.pone.0037953)

Frost RA, Nyström GJ & Lang CH 2003 Tumor necrosis factor-α decreases insulin-like growth factor-1 messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 144 1770–1779. (doi:10.1210/en.2002-220808)

Golikova EA, Lopatrnikova JA, Kovaľskaya-Kucheryavenko TV, Nepomnyashih VM & Sennikov SV 2013 Levels of TNF, TNF autoantibodies and soluble TNF receptors in patients with bronchial asthma. Journal of Asthma 50 705–711. (doi:10.3109/02770903.2013.796972)

Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, Gittoes NJ, Buckley CD, Raza K & Cooper MS 2008 Local and systemic glucocorticoid metabolism in inflammatory arthritis. Annals of Rheumatic Disease 67 1204–1210. (doi:10.1136/ard.2008.096062)

Ignatova ID, Kostadinova RM, Goldring CE, Nawrocki AR, Frey FJ & Frey BM 2009 Tumor necrosis factor-α upregulates 11β-hydroxysteroid dehydrogenase type I expression by CCAAT/enhancer binding protein-β in HepG2 cells. American Journal of Physiology. Endocrinology and Metabolism 296 E367–E377. (doi:10.1152/ajpendo.90351.2008)

Ishii-Yonemoto T, Masuzaki H, Yasue S, Okada S, Kozuka C, Tanaka T, Noguchi M, Tomita T, Fujikura J, Yamamoto Y et al. 2010 Glucocorticoid reactivation within cells intensifies NF-κB and MAPK signaling and reinforces inflammation in activated preadipocytes. American Journal of Physiology. Endocrinology and Metabolism 298 E930–E940. (doi:10.1152/ajpendo.00320.2009)

Kaur K, Hardy R, Ahasan MM, Eijken M, van Leeuwen JP, Filer A, Thomas AM, Raza K, Buckley CD, Stewart PM et al. 2010 Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Annals of Rheumatic Disease 69 1185–1190. (doi:10.1136/ard.2009.107466)

Khosravi R, Ka K, Huang T, Khalili S, Nguyen BH, Nicolau B & Tran SD 2013 Tumor necrosis factor-α and interleukin-6: potential interorgan

Author contribution statement

C L D, J B and A E Z conducted the work. P M S and G G L conceived and designed the research. C L D, M S C, P M S and G G L wrote the manuscript.

References
Rosenblatt JD, Lunt AJ, Parry DJ & Partridge TA 1995 Culturing satellite cells from living single muscle fiber explants. *In Vitro Cellular & Developmental Biology. Animal* **31** 773–779. (doi:10.1007/BF02634119)

Sal S, Esteses CL, Kelly V, Michaelidou Z, Anderson K, Coll AP, Nakagawa Y, Ohzeki T, Seckel JR & Chapman KE 2008 Glucocorticoid regulation of the promoter of 11β-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-β. *Molecular Endocrinology* **22** 2049–2060. (doi:10.1210/me.2007-0489)

Schwarzkopf M, Coletti D, Sassoon D & Marazzi G 2006 Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. *Genes and Development* **20** 3440–3452. (doi:10.1101/gad.412606)

Staab CA, Stegk JP, Haenisch S, Neiss E, Kobisch K, Ebert B, Cascorbi I & Maser E 2011 Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. *Chemico-Biological Interactions* **191** 104–112. (doi:10.1016/j.cbi.2010.12.027)

Stewart PM 2003 Tissue-specific Cushing’s syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. *European Journal of Endocrinology* **149** 163–168. (doi:10.1530/eje.0.1490163)

Stewart PM 2005 Tissue-specific Cushing’s syndrome uncovers a new target in treating the metabolic syndrome – 11β-hydroxysteroid dehydrogenase type 1. *Clinical Medicine* **5** 142–146. (doi:10.7861/clinmedicine.5-2-142)

Tomlinson JW, Durrani OM, Bujalska IJ, Gathercole LL, Tomlins PJ, Reuser TT, Rose GE, Curnow SJ, Stewart PM, Walker EA et al. 2010 The role of 11β-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. *Journal of Clinical Endocrinology and Metabolism* **95** 398–406. (doi:10.1210/jc.2009-0873)

Yamaki T, Wu CL, Gustin M, Lim J, Jackman RW & Kandarian SC 2012 Rel A/p65 is required for cytokine-induced myotube atrophy. *American Journal of Physiology. Cell Physiology* **303** C135–C142. (doi:10.1152/ajpcell.00111.2012)

Zhang J, Dong Y, Zou F, Wu M, Fan C & Ding Y 2013 11β-hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. *International Immunopharmacology* **17** 489–494. (doi:10.1016/j.intimp.2013.07.015)

Received in final form 8 January 2014
Accepted 9 January 2014
Accepted Preprint published online 10 January 2014